Becton Dickinson and Co
NYSE:BDX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Becton Dickinson and Co
Cash & Cash Equivalents
Becton Dickinson and Co
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Becton Dickinson and Co
NYSE:BDX
|
Cash & Cash Equivalents
$740m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-7%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash & Cash Equivalents
$2B
|
CAGR 3-Years
51%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
19%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Cash & Cash Equivalents
$2.9B
|
CAGR 3-Years
50%
|
CAGR 5-Years
20%
|
CAGR 10-Years
19%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash & Cash Equivalents
$4B
|
CAGR 3-Years
30%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash & Cash Equivalents
$8.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
10%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash & Cash Equivalents
$3.4B
|
CAGR 3-Years
29%
|
CAGR 5-Years
16%
|
CAGR 10-Years
17%
|
|
Becton Dickinson and Co
Glance View
Founded in 1897, Becton Dickinson and Co., commonly known as BD, embarked on its journey with the vision to improve medical discovery and diagnostics. Over the decades, BD has transformed from a small syringe and needle manufacturer to a global leader in the medical technology industry. Situated in Franklin Lakes, New Jersey, BD has carved out a prominent place through its steadfast commitment to addressing health care workers' requirements and enhancing patient outcomes. The company's diversified portfolio spans across three major segments: BD Medical, BD Life Sciences, and BD Interventional. This trinity of divisions underscores BD's prowess in producing a broad range of medical supplies, laboratory equipment, and diagnostic products that find their way into hospitals, research facilities, and clinics worldwide. The company operates primarily by innovating and supplying products that are indispensable to everyday medical care and scientific research. BD’s robust revenue stream is bolstered by its strategic approach to integrating new technologies and acquiring innovative smaller companies that complement its core offerings. Through strategies like these, BD continuously adapts to the evolving healthcare landscape. Its products, such as advanced syringes, safety-engineered devices, and sophisticated laboratory equipment, are deeply embedded in the healthcare system, making BD a critical part of the global push for improved health outcomes. The company’s blend of consistent product demand and strategic innovations secures a stable financial footing, allowing it to invest further in research and development while extending its market reach across the globe.
See Also
What is Becton Dickinson and Co's Cash & Cash Equivalents?
Cash & Cash Equivalents
740m
USD
Based on the financial report for Dec 31, 2025, Becton Dickinson and Co's Cash & Cash Equivalents amounts to 740m USD.
What is Becton Dickinson and Co's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-7%
Over the last year, the Cash & Cash Equivalents growth was 4%. The average annual Cash & Cash Equivalents growth rates for Becton Dickinson and Co have been 7% over the past three years , -26% over the past five years , and -7% over the past ten years .